Society for Neuro-Oncology Annual Meeting (SNO)

Patients with newly diagnosed glioblastoma saw improved progression-free survival when treated with tumor treating fields, pembrolizumab, and temozolomide versus historical control data.

Epigenetic lesions, and not just genetic mutations, can cause brain cancer, and one important implication of that observation is that precision-medicine genetic and genomic tools will miss epigenetic lesions that may drive tumor growth or drug resistance.

IDH1-mutant gliomas can affect adjacent, nonmalignant cells in ways that trigger seizures, according to research reported at the 21st Annual Scientific Meeting of the Society for Neuro-Oncology.

Computer analysis of subvisual data extracted from routine clinical MRI exams outperforms human experts at differentiating brain tumor recurrence from radiation necrosis.

In this interview we discuss findings from M12-356, an open-label, phase I, escalation cohort study of the investigational anti-EGFR antibody-drug conjugate ABT-414 for patients with EGFR-amplified recurrent glioblastoma.

Four years in the making, the new 2016 World Health Organization Classification of Tumors of the Central Nervous System includes new genetically identified entities and variants, allowing more diagnostic precision, and a new “layered” approach to diagnosis.

Caring for patients with brain tumors can have marked effects on the well-being of oncology clinicians, frequently leading to burnout, and authors of an ongoing survey study aim to get a clearer picture of those impacts.

The anti-inflammatory ibudilast shows early preclinical promise against glioblastoma cell lines when combined with temozolomide, according to new research.

In this interview we discuss updates, challenges, and contributing factors associated with pediatric brain cancers.

In this interview we discuss fatigue, cognitive dysfunction, and psychiatric problems in patients with glioma and review which patients are more likely to encounter these issues.

Innovative “adaptive” clinical trial designs are using molecular tools and biomarkers in ways that will streamline research efforts and bring new treatments more quickly to regulatory approval and clinical use.

Expression of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) is associated with poor glioblastoma outcomes.

Pregnancy might stimulate tumor growth among women diagnosed with gliomas, according to a single-institution retrospective review of cases.

HLA-A2-positive glioblastoma patients experienced more frequent immune responses to the dendritic-cell immunotherapy IDT-107, responses that may be associated with improved survival.

Adding adjuvant gene-mediated cytotoxic immunotherapy using aglatimagene besadenovec and valacyclovir to standard of care improves survival among patients undergoing surgery for newly diagnosed malignant glioma.

Targeted MAPK-pathway inhibitor therapies appear to have reduced tumor sizes in four children’s inoperable astrocytomas-tumors that had progressed despite chemotherapy.

Adding procarbazine, CCNU, and vincristine to radiotherapy offers pronounced survival benefits for patients with low-grade gliomas harboring IDH1 R132H mutations.

Serum matrix metalloproteinase 9 (MMP-9) and HER2 extra-cellular domain (HER2-ECD) might be predictive biomarkers for the metastasis of breast cancer to the brain, according to a case-control study.

Adding rindopepimut to bevacizumab therapy was associated with improved long-term survival in patients with recurrent EGFRvIII-positive glioblastoma.

Despite promising progression-free survival results, the combination of bevacizumab and lomustine for the treatment of first recurrence in glioblastoma did not improve overall survival, according to findings from the phase III EORTC-26101 trial.

New research suggests that characterizing low-grade gliomas according to molecular markers may be a more useful approach in order to guide treatment decisions.

A core set of symptoms are common across brain tumor patients and underscore the complexity of brain tumors and their management.

Depressive symptoms and impaired executive functioning, both common in patients with glioblastoma, are independently associated with shorter overall survival.

The immunotherapeutic rindopepimut with bevacizumab yielded a significant survival improvement in relapsed glioblastoma patients with a EGFRvIII mutation.

A phase I trial of an oncolytic polio/rhinovirus vaccine was safe and showed promising efficacy in patients with recurrent glioblastoma.

Treating newly diagnosed glioblastoma with “tumor treating fields” is a safe and effective therapeutic option, according to a new trial.

A combination of bevacizumab and lomustine showed promise in a randomized phase II trial of patients with recurrent glioblastoma, according to study results.

The addition of procarbazine, CCNU, and vincristine to RT in patients with low-grade glioma prolongs progression-free and overall survival vs RT alone.

As part of our Society of Neuro-Oncology annual meeting coverage, we discuss quality of life issues and neurologic rehabilitation in patients with neuro-oncologic diseases.